Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What are the side effects of the drug ultomiris?

See the DrugPatentWatch profile for ultomiris

Common Side Effects of Ultomiris

Ultomiris (ravulizumab) causes upper respiratory tract infections in about 28% of patients, nasopharyngitis in 23%, headache in 21%, and nausea in 13%. Other frequent issues include fatigue, diarrhea, musculoskeletal pain, dizziness, and injection-site reactions.[1][2]

Serious Side Effects and Risks

Serious infections occur due to meningococcal risk—increased susceptibility lasts for the drug's duration plus 8 months after the last dose. Patients need vaccination and prophylaxis. Other risks include meningococcal sepsis, pneumonia, and rare Haemophilus influenzae infections. Infusion-related reactions (fever, chills, back pain) affect 4-7%; severe anaphylaxis is possible. Hemolysis may worsen upon discontinuation, requiring monitoring.[1][2][3]

Side Effects by Condition Treated

In paroxysmal nocturnal hemoglobinuria (PNH), common effects mirror the overall profile, with 2% discontinuing due to adverse events. For atypical hemolytic uremic syndrome (aHUS), hypertension (17%) and pyrexia (16%) stand out alongside infections. In generalized myasthenia gravis (gMG), COVID-19 infections and falls are notable, though possibly disease-related.[2][3]

What Happens During Infusion or Injection

Reactions during or within hours of administration include chest tightness, hypertension, tremor, and dyspnea. Premedicate with antihistamines or pain relievers if prior issues occur; slow infusion rate for management.[1][3]

Long-Term Risks and Monitoring

No new safety signals emerge after 4+ years in PNH/aHUS trials. Monitor CBC, kidney function, and infection signs. Avoid live vaccines; antibiotic prophylaxis recommended for some.[2]

Differences from Soliris (Eculizumab)

Ultomiris, a longer-acting version, shows similar side effect profiles but lower infection rates due to less frequent dosing (every 8 weeks vs. every 2). Meningococcal risk persists identically.[3]

[1]: Ultomiris Prescribing Information, AstraZeneca, 2023. https://www.azpicentral.com/piultomiris/ultomiris.pdf
[2]: Drugs.com - Ultomiris Side Effects. https://www.drugs.com/sfx/ultomiris-side-effects.html
[3]: FDA Label for Ultomiris. https://www.accessdata.fda.gov/drugsatfda
docs/label/2023/761214s017lbl.pdf



Other Questions About Ultomiris :

Is ultomiris better than soliris?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy